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Abstract
Immunotherapy has revolutionized cancer treatment over the past decade.
Nonetheless, prolonged survival is limited to relatively few patients. Can-
cers enforce a multifaceted immune-suppressive network whose nature is
progressively shaped by systemic and local cues during tumor development.
Monocytes bridge innate and adaptive immune responses and can affect
the tumor microenvironment through various mechanisms that induce im-
mune tolerance, angiogenesis, and increased dissemination of tumor cells.
Yet monocytes can also give rise to antitumor effectors and activate antigen-
presenting cells. This yin-yang activity relies on the plasticity of monocytes
in response to environmental stimuli. In this review, we summarize current
knowledge of the ontogeny, heterogeneity, and functions of monocytes and
monocyte-derived cells in cancer, pinpointing the main pathways that are

























































































The clinical results obtained with immune checkpoint inhibitors (ICIs) (1) and chimeric antigen
receptor T cells (2) have changed the landscape of tumor treatment, highlighting immunotherapy
as the latest breakthrough.There is a general consensus pinpointing T cells as the major players in
the antitumor response. Indeed, the evaluation of T lymphocyte density (i.e., cell quantity), spatial
localization (i.e., invasive margin, tumor core, or tertiary lymphoid structures), cell types (i.e., T
helper cells and cytotoxic, memory, and exhausted T cells), and functional immune orientation
stimuli (i.e., adhesion receptors, chemokines, cytokines) within the tumor could predict survival
in colorectal cancer more accurately than the classical staging systems (3). Indeed, by combining
immunohistochemical analysis and gene profiling data for tumor-infiltratingT cells, a new param-
eter, called an Immunoscore, has been developed to estimate the adaptive immune composition
of the tumor microenvironment (TME) and validated as a predictive biomarker in several malig-
nancies (4). Based on their Immunoscore, tumors may be segregated into four major groups: hot,
altered-excluded, altered-immunosuppressed, and cold. Immune deserts (cold tumors) are charac-
terized by the absence of T cell infiltration due to a lack of the cells and/or mechanisms required
for T cell priming or activation (i.e., low tumor mutational burden and poor antigen presenta-
tion). A tumor with an immunosuppressed TME is instead defined by an intermediate infiltration
of exhaustedT cells [i.e.,T cell immunoglobulin andmucin domain-containing protein 3 (TIM3)–
expressing cells] and a high density of soluble inhibitory mediators [e.g., interleukin (IL)-10] and
immune-suppressive cells [e.g., regulatory T cells (Tregs)]. T cell exclusion inside the tumor core,
induced by the presence of aberrant vasculature and fibrotic nets, is the main feature of an altered-
excluded immune tumor. Finally, immune-replete tumors (hot tumors) are characterized by high
infiltration of programmed cell death 1 (PD-1)- or cytotoxic T lymphocyte–associated antigen 4
(CTLA4)-expressing cytotoxic T lymphocytes (CTLs) and tumor cells expressing costimulatory
or drug-targetable molecules [e.g., programmed death-ligand 1 (PD-L1)] that are able to main-
tain T cell fitness (4, 5). Interestingly, hot tumors are also characterized by the presence of local
inflammation, and, moreover, they respond to immunotherapy (5). As expected, T cell compo-
sition inside the TME partially depends on the mutational landscape of the tumor (6). In fact,
oncogene activation in cancer cells favors the secretion of soluble factors (i.e., growth factors, cy-
tokines, and chemokines) that alter the TME to favor T cell migration and localization inside the
cancer core; the aberrant expression of neoantigens, potential immunotherapy targets, can fuel
antitumor responses by activating CTLs (7). However, oncogenes can also activate immune regu-
latory circuits that have a negative impact on adaptive immunity. For instance, in LSL-KrasG12D/+;
LSL-Trp53R172H/+; Pdx1-Cre mice (the KPC mouse model), the simultaneous expression of mu-
tant KRASG12D and mutant p53R172H in pancreatic epithelial cells promotes tumor growth and
increases the secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF), which
favors the accumulation of immunosuppressive myeloid cell subsets (8).
Although the correlation between cancer genotype and infiltration of adaptive immune cells is
quite solid in preclinical models, a deeper understanding of cancer–immune cell cross talk is still
lacking. Despite the success of cancer immunotherapy, the majority of cancer patients currently
do not benefit from immune-based treatments. A great deal of evidence suggests that myeloid cells
have a direct role in promoting, supporting, and maintaining tumor growth, either through direct
interplay with cancer cells, manipulation of T cell composition and activity (e.g., inhibition of T
cell migration or activation), or alteration of the stromal architecture (e.g., matrix protein remod-
eling) (9, 10). In particular, monocytes serve as a principal source of long-lived TME-infiltrating
cells such as macrophages and dendritic cells (DCs), and during cancer progression, they con-
tribute to cancer immune evasion by differentiating into immune regulatory cells. Interpreting























































































the heterogeneity of monocytes and their roles at different stages of cancer progression is essen-
tial for improving our knowledge of TME composition and evolution. In this review, we discuss
our current understanding of the tumor-dependent mechanisms that shape myeloid cell polariza-
tion, differentiation, and function by altering precise molecular pathways.
2. TUMOR-INDUCED ALTERNATIVE MYELOPOIESIS
As occurs during systemic bacterial infections, myeloid cell turnover is dramatically boosted dur-
ing cancer progression. The recruitment of myeloid cells to the primary tumor site is supported
by the continuous production and mobilization of cells from the bone marrow (BM), causing a
state of emergency in which monocytes can be generated from alternative pathways or precur-
sors (11). Given the dynamics of recruitment and differentiation into different myeloid lineages
and the involvement of the BM niche, the myeloid circuits affected by tumors are not just local
and confined to the TME but spread systemically. The accumulation of cells in the circulation, in
addition to the TME, is a sign of the corrupted promyelopoietic process induced by tumors (12)
(Figure 1).
The classical view of hematopoiesis implies that hematopoietic stem cells (HSCs) in the
BM give rise to heterogeneous multipotent progenitors (MPPs), which in turn differentiate in
a colony-stimulating factor (CSF)-1-dependent manner (13) into common myeloid progeni-
tors (CMPs). Granulocyte and monocyte precursors (GMPs), originating from the CMPs, dif-
ferentiate into monocytes through a series of steps, going from monocyte and dendritic cell
precursors (MDPs) to unipotent common monocyte progenitors (cMoPs) (14, 15). Differenti-
ated monocytes circulating in the blood can be divided into two main subpopulations in mice,
Ly6ChiCX3CR1low (classical) and Ly6ClowCX3CR1hi (nonclassical) cells, and into three subsets
in humans, CD14hiCD16low/− (classical or inflammatory), CD14lowCD16hi (nonclassical or pa-
trolling), and CD14hi/midCD16+ (intermediate). However, recent single-cell and family tracing
methodologies, including single-cell RNA sequencing (RNA-seq), mass cytometry, and cellular
barcoding, raise questions about the classical branching nature of the hematopoietic tree and sug-
gest that lineage commitment is already present in oligopotent progenitors (16). Specifically, this
redefined model envisions a developmental shift in the progenitor cell architecture from the fetus
(where many stem and progenitor cell types are multipotent) to the adult (where the stem-cell
compartment is multipotent, but the progenitors are unipotent) and provides a revised frame-
work for understanding hematopoiesis in health and disease. Seminal work defined the role of
hematopoietic cytokines and growth factors in shaping hematopoiesis (17). Under steady-state
conditions, myeloid lineage commitment and differentiation are orchestrated by both lineage-
specific cytokines, mainly CSFs (such as CSF-1, CSF-2, and CSF-3) and transcription factors
(TFs). Focusing on monopoiesis, CSF-1 receptor (CSF-1R), which binds the ligands CSF-1 and
IL-34, regulates the development of monocytes in the BM and, therefore, is considered the master
regulator of monocyte differentiation (18). In mice deficient for CSF-1R and CSF-1, the number
ofmonocytes in the blood is profoundly reduced (18). In patients with solid cancers, hematopoiesis
is generally perturbed, with a bias toward myeloid differentiation at the expense of erythroid and
lymphoid precursor polarization (19). Besides the function of the lineage-commitment cytokines
mentioned before, other tumor-secreted, proinflammatory cytokines [e.g., IL-1β, IL-6, interfer-
ons (IFNs), and tumor necrosis factor-α (TNF-α)] and Toll-like receptors (TLRs) can influence
the rate and route of HSC differentiation (20). This can lead to the accumulation of cells with im-
munosuppressive activity, primarily myeloid-derived suppressor cells (MDSCs), tumor-associated
macrophages (TAMs), and regulatory DCs (21). In the MMTV-PyMT mouse model of sponta-
neous breast cancer, the release of CSF-2 by tumor cells was shown to induce the expansion of
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Figure 1 (Figure appears on preceding page)
Tumor-induced emergency myelopoiesis and its impact on the bone marrow, peripheral blood, and tumor microenvironment. Tumors
produce and secrete a variety of soluble factors that affect steady-state myelopoiesis. Text next to or below the cell types shows human
phenotypes (black text) and/or mouse phenotypes (blue text). Abbreviations: ARG, arginase; CCL, C-C motif chemokine ligand; CCR,
C-C motif chemokine receptor; cDC, conventional dendritic cell; CDP, common dendritic cell progenitor; c/EBP, CCAAT/enhancer-
binding protein; cFLIP, cellular FLICE (FADD-like IL-1β-converting enzyme)-inhibitory protein; cMoP, common monocyte
progenitor; CMP, common myeloid progenitor; CSF, colony-stimulating factor; CX3CL, C-X3-C motif chemokine ligand; CXCR,
C-X-C motif chemokine receptor; FLT3L, Flt3 ligand; GM-CSF, granulocyte-macrophage colony-stimulating factor; GMP,
granulocyte and monocyte progenitor; HLA-DR, human leukocyte antigen DR; HSC, hematopoietic stem cell; IRF, interferon
response factor; KLF, Krüppel-like factor; MDP, monocyte and dendritic cell progenitor; MHC-II, major histocompatibility
complex II; M-MDSC, monocytic-myeloid derived suppressor cell; MoDC, monocyte-derived dendritic cell; NF-κB, nuclear factor
κB; NOS, nitric oxide synthase; PD-L, programmed cell death ligand; pre-DC, dendritic cell precursor; STAT, signal transducer and
activator of transcription; TAM, tumor-associated macrophage; Tip-DC, TNF-α/inducible (i)NOS-producing dendritic cell; TNF,
tumor necrosis factor; TRM, tissue-resident macrophage; VEGF, vascular endothelial cell growth factor; XCR, X-C motif chemokine
receptor. Figure adapted from an image created using Servier Medical Art (CC BY 3.0 Unported).
HSCs to replenish the short-lived MDSCs (22). Similarly, in Lewis lung carcinoma, the increased
signaling of insulin-like growth factor type 1 receptor (IGF-1R) in HSCs leads to a skewed dif-
ferentiation of Lin−Sca1+CD117+ (LSK) progenitors toward myeloid cells with a suppressive
phenotype (23). Even though this is true for some tumors, the majority of solid tumors do not
secrete hematopoietic cytokines, yet they still present with altered hematopoiesis. In this scenario,
the altered hematopoiesis can be supported by TNF-α released by immune cells, mainly CD4+ T
cells, in several mouse models of tumorigenesis. Depletion of CD4+ and CD8+ T cells was shown
to normalize the number of LSKs and CMPs, resulting in a significant reduction in MDSCs and
associated immunosuppression. Alternatively, the loss of TNF-α in TNF receptor (TNFR)1/2-
deficient mice or the neutralization of TNF-α by blocking antibodies normalized hematopoiesis
and reduced the number of peripheral granulocytic (G)- and monocytic (M)-MDSCs (24, 25).
Moreover, TNF-α not only increases the number of MDSCs by regulating HSCs but also di-
rectly enhances MDSC survival through cellular FLICE (FADD-like IL-1β-converting enzyme)-
inhibitory protein (c-FLIP)-mediated inhibition of caspase-8 (26), suggesting that targetingTNF-
α could restore cancer immune surveillance and enhance the efficacy of cancer immunotherapy
(27).
In addition to being affected by hematopoietic cytokines and growth factors, HSCs can also
be modulated by trained immunity, at least during inflammation and sepsis. Through epigenetic
and metabolic switches, administration of β-glucan to mice induces an expansion of myeloid pro-
genitors, mainly LSKs and MPPs, which then differentiate into myeloid cells that secrete proin-
flammatory mediators such as IL-1β, CSF-2,TNF-α, and IL-6, providing a robust and quick (e.g.,
trained) response to subsequent insults (28). CSF-2 was also shown to be a stimulus for trained
immunity, resulting in increased TNF-α production upon subsequent lipopolysaccharide stimula-
tion through a mechanism dependent on theMAPKs ERK1 and ERK2 (29). Like in inflammation
and sepsis, a similar program may also occur in cancer. In this context, the function of MDSCs
is determined by their epigenetic program, including DNA methylation, histone modifications,
and modulatory noncoding RNAs (30). A similar process occurs when monocytes infiltrate tu-
mors and differentiate into TAMs that promote tumor growth and suppress antitumor immune
responses (31). Epigenetic reprogramming is a central feature of TAM differentiation; long-term
histone modifications, such as changes in H3K4me3 and H3K9me3, underlie and induce a protu-
morigenic profile in these cells (31). Rewiring the epigenetic and functional program of MDSCs,
TAMs, or both by inducing trained immunitymay be a compelling option for cancer immunother-
apy (28).While the exact impact of trained immunity on HSC precursors has not been fully clar-
ified in the context of cancer, and in human cancer in particular, new data suggest that targeting























































































trained immunity, in particular myeloid-biased progenitors in the BM,may facilitate the induction
of durable, reliable, and precise responses without severe immune-related adverse effects.
As mentioned earlier, the commitment toward monocyte differentiation is determined by
major lineage-determining TFs, namely PU.1, CCAAT/enhancer-binding protein (c/EBP)β and
c/EBPα. Together with IFN regulatory factor (IRF)8 and Krüppel-like factor (KLF) 4, PU.1 binds
to chromatin to coordinate the activation of genomic regions necessary for monocyte origin and
differentiation. Indeed, mice lacking PU.1 are not vital and the transfer of stem cells carrying the
genetic ablation of PU.1 favors a skewed myelopoiesis with a profound contraction in monocytes
andDCs and an expansion of lymphocytes (32).Moreover, together with IRF8, PU.1 binds to pro-
moters and enhancers supporting the monocyte genetic program. IRF8-deficient mice accumu-
late monocyte-committed progenitors and monoblasts that are unable to differentiate into mature
monocytes, suggesting that IRF8 is dispensable for monocyte lineage commitment but regulates
later maturation stages (33). Additionally, IRF8 affects the expression of monocyte genes through
the direct activation of the TF KLF4, induces the activation of enhancers to sustain the expression
of monocyte-related genes, and interacts with c/EBPα to inhibit the granulocyte differentiation
program (11).
Proteins of the c/EBP family can have opposing impacts on the development of myeloid cells
(11). Indeed, while c/EBPα inhibits the development of nonmyeloid cells by blocking the function
of their specific TFs, c/EBPβ must contribute directly to monopoiesis since mice lacking c/EBPβ
have a drastic reduction in the number of circulating monocytes (34). Of note, c/EBPβ controls
altered myelopoiesis in cancer, contributing to the accumulation of MDSCs and the maintenance
of an immunosuppressive TME (35). Fate-mapping analysis and in-depth RNA interrogation at
the single-cell level have revealed what seems to be an endless series of monocyte progenitors,
hinting that the activation of the monocyte gene-specific lineage is sustained by TFs acting in a
combinatorial way and is functionally controlled by autoregulatory loops (34). Whether the TFs
themselves are regulated by environmental or intrinsic signals is still a matter of debate.Transcrip-
tomic data identified an RNA-binding protein named DZIP3 as an E3 ubiquitin ligase that might
regulate monocyte development by controlling TF access to lineage-specific promoter and/or
enhancer regions in progenitor cells (36). Recently, single-cell RNA-seq revealed zinc finger E-
box-binding homeobox 2 (Zeb2) and GATA2 as TFs implicated in monocyte differentiation, with
Zeb2 deletion leading to the depletion of Ly6Chi monocytes in the BM and GATA2 mutations
being associated with monocyte deficiencies in humans (37, 38).
During emergency hematopoiesis, like in cancer or inflammation, there is an accumulation
of monocytes that have escaped the canonical MDP-cMoP-monocyte developmental pathway
and acquired similarities to neutrophils, such as the neutrophil-like Ly6Chi monocytes originat-
ing from GMPs (39). Interestingly, GMP-derived neutrophil-like Ly6Chi monocytes have a high
level of expression of growth factor independent 1 (Gfi1), whose normal role is to sustain granu-
lopoiesis (39). Yet, whether Gfi1 plays a role in the functional programming of these monocytes,
such as by regulating the expression of intracellular granule content, remains to be determined.
Intense investigation is ongoing to clarify whether other noncanonical monocytes also play a role
in cancer. This is the case for segregated nucleus-containing atypical Ly6Clow monocytes (SatMs),
a monocyte subset that appears during lung fibrosis (40). Fate-mapping studies and extensive pro-
teomic analysis revealed that SatM cells derive from GMP FcɛR1+ progenitors, are character-
ized by a highly active c/EBPβ-associated gene program, and are also rich in granules containing
myeloperoxidase and neutrophil elastase, similar to neutrophils (40). At present, the lack of sur-
face markers to unequivocally distinguish SatM (Ly6ClowCeacam1hiMsr1hi) cells from nonclassi-
cal Ly6Clow monocytes and neutrophil-like Ly6Chi monocytes from classical Ly6Chi monocytes























































































prevents these populations from being assessed in primary and metastatic tumors, as well as the
complete tracking of their ontogeny in cancer in both humans and mice.
Epigenetic modifications represent another layer for hematopoiesis regulation, including but
not restricted to both distribution and access of TFs to chromatin. Even though our knowledge of
how and when epigenetic modifications occur during both steady-state and cancer-driven emer-
gency myelopoiesis is just being defined, some paradigms are emerging.Mice with reduced DNA
(cytosine-5)-methyltransferase (DNMT)1 activity have only myelo-erythroid cells and lack lym-
phoid progeny (41). Moreover, CMPs differentiate into megakaryocyte-erythroid lineages when
histone deacetylase 1 (HDAC1) expression is sustained byGATA1,whereas whenHDAC1 expres-
sion is downregulated by c/EBP TFs, committed CMPs give rise to myeloid cells, in particular
granulocytes (42). Among several epigenetic modifications, DNA methylation is one of the most
studied in the context of hematopoiesis, being involved in regulating HSC self-renewal, facilitat-
ing the commitment to lymphoid or myeloid progeny, and establishing the identities of differenti-
ated cell types (11). DNMT1 is indispensable for protecting HSCs from the premature activation
of differentiation programs (41), and DNMT3A and DNMT3B are required to silence the ex-
pression of TFs related to self-renewal and multipotency, such as RUNT-related transcription
factor 1 (RUNX1) and GATA3 (43). In addition, analysis of the epigenome of HSCs has revealed
that genes encodingTFs that are important for hematopoietic cell differentiation, such as c/EBPα,
PU.1, and paired-box protein (PAX)5, have low levels of DNA methylation and are enriched in
both activating H3K4me3 and repressive H3K27me3 modifications (44). Myelo-monocytic cells
are evolutionarily more ancient than the lymphoid compartment, and the DNA methylation pat-
terns of HSCs resemble those seen in myeloid cells rather than lymphoid cells (41), suggesting an
intrinsic myeloid bias of the HSC methylome (45).
3. THE TUMOR MICROENVIRONMENT SHAPES MONOCYTE
DIFFERENTIATION IN SITU
Monocytes are circulating cells able to migrate inside tissues in response to damage signals (46).
Similarly, monocytes can be recruited to the TME, where they locally differentiate (47, 48)
(Figure 1). However, the cues that drive the monocyte fate decision between remaining a mono-
cyte, further differentiating, or undergoing programmed cell death are still not completely known.
Recent data from RNA-seq on myeloid cell composition in the TME of human breast cancers
highlight a monocyte-activation gene signature that supports the existence of a trajectory from
bloodmonocytes to intratumoral monocytes and,more interestingly, to different myeloid cell sub-
sets (49). In general, TME-infiltrating, monocyte-derived cells can be grouped into three main
subsets: TAMs, tumor-associated DCs (TADCs), and MDSCs.
3.1. Tumor-Associated Macrophages
TAMs are the most prominent myeloid cell subset inside the TME (50). TAMs have an intrin-
sically heterogeneous nature, and their presence is generally associated with poor prognosis in
different tumors (51), even though in some cancers, such as endometrial cancer, a clear corre-
lation between TAM infiltration and improved cancer-patient survival has also been described
(52). Recently the heterogeneity of breast (53), lung (47), liver (54), and renal (55) carcinoma pa-
tients’ immune ecosystems was deeply mapped by single-cell sequencing able to identify up to
17 different TAM clusters, each characterized by a specific genetic profile. In liver cancer, for
example, TAM-like cells highly express a marker gene, SLC40A1, that encodes ferroportin, an
iron exporter that is able to regulate the release of proinflammatory cytokines including IL-6,























































































IL-23, and IL-1β via TLR-mediated signaling.Moreover, this peculiar TAM-associated gene sig-
nature is significantly associated with a survival disadvantage for patients, highlighting the role
of iron metabolism in shaping innate immunity into a protumor component (54). In breast can-
cer, TAM infiltration correlates with tumor aggressiveness, as evidenced by a greater macrophage
presence in the more aggressive luminal B tumors compared to the luminal A subtype. Notably,
in luminal B tumors, estrogen receptor–positive cancer regions are massively infiltrated by im-
munosuppressive PD-L1/CD38-expressing TAMs, which are preferentially located in the inner
space of the tumor while monocytes are present in the juxta-tumoral tissue (53). These spatial
and genetic features of TAMs could partially explain the limited success of ICI-based therapy in
estrogen receptor–positive breast-cancer patients. Interestingly, TAM molecular signatures from
KEP or NeuT transgenic mice, whose phenotypes resemble human invasive lobular carcinoma
(ILC) andHER2+ tumors, respectively, are unique, suggesting that the cancer subtype dictates the
TAM phenotype (56). Furthermore, the KEP-derived TAM signature is consistently correlated
with poor overall survival in ILC but not in triple-negative breast-cancer patients, indicating that
translation of mouse TAM signatures to patients is cancer-subtype dependent (56).
TAMs can be broadly defined on the basis of their origin as either tissue-resident macrophages
(TRMs), which develop from fetal–yolk sac or fetal-liver progenitors (14, 57), or monocyte-
derived macrophages (58), although the precise kinetics of monocyte to TAM differentiation is
still not completely understood. In a seminal work, classical monocytes were found to upregu-
late markers of TAM terminal differentiation (e.g., F4/80) in primary mouse breast tumors within
5 days of their arrival, following the activation of the transcriptional regulator of Notch signaling
RBPJ (58). Unlike other hematopoietic-derived cells, TRMs derive from two precursors during
embryonic development (59). In an early phase of embryogenesis, macrophages originate from
the yolk sac, directly from erythro-myeloid progenitors (EMPs) and independently of the tran-
scriptional control of c-Myb. These macrophages seed some tissues and constitute microglia, for
example. Alternatively, during the late phase of embryonic development, fetal monocytes gen-
erated from c-Myb+ EMPs in the fetal liver can give rise to the majority of TRMs (59). The
long-standing question regarding the kinetics and extent of the circulating monocyte contribu-
tion to TRM replacement during homeostasis, inflammation, and disease was recently addressed
by the generation of a series ofMs4a3TdT reporter andMs4a3Cre andMs4a3CreERT2 fate-mapping
mouse models, which were developed to trace monocytes (60). As mentioned before, monocytes
are hypothesized to arise from the following hierarchical sequence: CMP to GMP, then MDP,
cMoP, and finally monocyte (12).However, this model was recently challenged by Yanez et al. (39),
who proposed that MDPs arise directly from CMPs independently of GMPs and that GMPs and
MDPs give rise to distinct monocytes through monocyte-committed progenitors and cMoPs, re-
spectively. These two pathways may be mobilized in response to different microbial components
to which the immune system is exposed (39). Fate-mapping studies using theMs4a3Cre model also
showed that MDPs do not arise from GMPs, and in turn, they do not generate cMoPs. In partic-
ular, Ms4a3 was found to be a marker for BM-resident GMPs and cMoPs and may be suitable for
labeling GMPs and their progeny, including monocytes.While TRMs in the brain, i.e., microglia,
do not undergo monocyte-dependent replacement after birth, those in other tissues exhibit ei-
ther fast (dermis) or slow (kidney) replacement under steady-state conditions (60). Moreover, the
monocyte contribution to inflammation caused by different stimuli is variable and associated with
the death of tissue macrophages, which are monocytes that are able to seed the tissue and fill the
empty niches left after macrophage dismissal (60).Within the tissues, subsets of macrophages co-
exist and respond differently to the same homeostatic and damage signals, and these fate-tracing
models will be extremely useful in the future to study how cancer modifies the balance between
different subsets.























































































Recent insights suggest that resident macrophages exhibit different transcriptional features
in the TME compared to their monocyte-derived counterparts. Indeed, TRMs have increased
expression of genes involved in tissue remodeling and wound healing, while monocyte-derived
TAMs are enriched in genes associated with immunosuppression and antigen presentation (61),
suggesting a distinct contribution to tumor progression. RNA-seq analysis of TAMs purified from
endometrial and breast cancers and compared with TRMs from healthy tissues validated the pres-
ence of TME cues that are able to modulate TAM features independently from their precur-
sor cells (62). Moreover, monocyte-derived TAMs are transcriptionally distinct from circulating
monocytes, and TAMs located in collagen-rich stroma differ from TAMs placed in perivascular
cancer lesions, suggesting that the differentiation trajectory of TME-infiltrating monocytes de-
pends on their spatiotemporal infiltration within the tumor tissue (63).While some TRMs main-
tain expression of tissue-associated markers (62), the heterogeneous phenotype of TAMs makes
their enumeration inside TMEs quite challenging, and new strategies need to be developed to
define their functional state. Indeed, a TAM’s functional state is strictly controlled by epigenetic
and molecular pathways (31), and this plasticity is oversimplified into the classical (M1) or alter-
native (M2) macrophage polarization model based on in vitro studies with macrophages under-
going either IFNγ or IL-4 stimulation, respectively (64). Even if the classification of M1 and M2
macrophages cannot take into consideration the broad spectrum of macrophage activation that
occurs in vivo, defining only the extremes of macrophage plasticity, it is interesting that this di-
chotomy may still underlie a correlation between TME-infiltrating TAMs and patient outcome.
M2-polarized macrophages are involved in tissue remodeling, repair, and angiogenesis processes,
mostly via the induction of arginase (ARG)1- and IL-10-associated networks; in line with these
functions, the frequency of M2-like TAMs in the TME generally correlates with poor prognosis
in a pan-cancer analysis (65), and thus M2 macrophages are considered protumorigenic elements.
Conversely, M1-polarized macrophages have been traditionally classified as antitumor effectors
since they express high levels of inflammatory mediators, such as TNF-α, nitric oxide (NO) [via
inducible NO synthase (iNOS; also called NOS2)], and reactive oxygen species (ROS), which are
able to directly kill tumor cells and stimulate an antitumor T cell response (66).
3.2. Tumor-Associated Dendritic Cells
TADCs represent aminor population in theTMEbut their immune control function is significant
since they are specialized in antigen processing and presentation to naive T cells (67, 68). Indeed,
high densities of TADCs are associated with increased overall survival for patients with breast,
lung, or head and neck cancer (67), as well as with an increased antitumor T cell response (69).
Moreover, DCs contribute to the generation of tertiary lymphoid structures (TLSs) inside the
TME.TLSs are ectopic lymphoid organs in nonlymphoid tissues, such as stroma and the invasive
margin and/or core of different tumors, that are formed upon long-lasting exposure to inflam-
matory signals. They are composed of a T cell–rich zone containing mature DCs juxtaposed with
B cell follicles that contain a germinal center and are surrounded by plasma cells. TLSs might
represent privileged sites for local presentation of neighboring tumor antigens to T cells by
DCs, which activate effector-memory T helper cells, effector-memory CTLs, memory B cells,
and antibody-producing plasma cells, as elegantly reviewed by Fridman and colleagues (70).
Interestingly, TLS presence is associated with a favorable prognosis for most solid malignancies
(71) and correlates with the immunotherapy response in melanoma (72) and renal-cell carcinoma
patients (73).
The two main conventional DC subsets (cDCs) located within tumors, defined as cDC1s
and cDC2s, originate from lineage-restricted precursors characterized by the activation of the
BAFT/IRF8- and IRF4-dependent pathways, respectively (67). Interestingly, these circulating























































































precursors can also be detected inside TMEs (67). cDC1s are not only involved in promoting
T cell activation; they cross-present tumor antigens, are the primary producers of IL-12, and also
promote CD8+ T cell proliferation and effector functions, which correlate with higher rates of
responsiveness to chemotherapy (67). Conversely, cDC2s preferentially control the activation of
CD4+ T cells though major histocompatibility complex (MHC)-II-mediated pathways (68). Sim-
ilar to TAMs, the classification of TADCs is probably simplified, and these cell subsets show a
great deal of heterogeneity. Single-cell analysis of innate immune cells in lung adenocarcinoma
demonstrated the presence of two distinct clusters of TADCs, one expressing high levels of CD1c,
CXCR1, and IRF4 and resembling cDC2s (the CD1c+ DC cluster), while the other was character-
ized by CD207, CLEC9A, and XCR1 expression typical of cDC1s (the CD141+ DC cluster) (47).
Interestingly, the CD141+ DC cluster but not the CD1c+ DC cluster was significantly reduced
in tumors compared to normal tissue, suggesting that tumor escape might be preferentially linked
to a contraction in cDC1-like cells. Indeed, the tumor-infiltrating CD141+ DC subset expresses
lymphotoxin beta transcripts that can help preserve TLS architecture and favor lymphocyte re-
cruitment (47).
The TADC pool inside the TME can also be maintained by C-C motif chemokine receptor
(CCR)2+-monocyte differentiation after their infiltration into the tumor mass. Indeed, monocyte
adoptive transfer restores TADC-mediated antitumor responses in CD11c-DTR tumor-bearing
mice in which DCs are genetically depleted (74). Normally, monocyte-to-TADC differentia-
tion in the TME is characterized by the acquisition of specific markers (i.e., CD11c, CD103,
CD80, CD86), morphological changes, and antigen-presenting cell (APC)-associated functions
(75). Monocyte-derived TADCs are usually immunogenic, due to the upregulation of positive
costimulatory molecules and IL-12 secretion (76), even though in some contexts they can help
dampen protumor immune responses by abrogating T cell functions (77). Since monocyte con-
version in either protumoral or antitumoral TADCs may diverge in the TME of different cancer
types, one challenge for the field is the identification and characterization of molecular switches
that underlie different TADC functional states, which goes beyond standard phenotypical char-
acterization. In line with this goal, Sharma and colleagues (78) demonstrated that Ly6C+CD103+
monocyte-derived (Mo)DCs in the TME are distinct from CD103+ cDCs and derive from both
cMoPs and circulating M-MDSCs. This cell conversion is induced by TME-associated local in-
flammation and depends on the activation of p53, which controls upregulation of Batf3 and ac-
quisition of the MoDC phenotype. Furthermore, Ly6C+CD103+ MoDC polarization is affected
by PTEN+ Tregs, suggesting that the TME immune composition can steer monocyte cell plas-
ticity (78).We also demonstrated that monocytes can differentiate into potent APCs in the TME,
acquiring distinctive features of DCs called TNF-α/iNOS-producing (Tip)-DCs that are spe-
cialized in innate immunity against pathogens. Tumor-infiltrating Tip-DC generation requires
CD40/CD40L signaling and offers a source of potent antitumor elements, not only APC activ-
ity but also TNF-α- and NO-dependent tumor killing, which promote the antitumor activity of
transferred T lymphocytes bearing a T cell receptor with high affinity for tumor antigens (79).
These two examples of monocyte differentiation in TMEs suggest that monocyte-derived DCs, in
addition to cDCs, participate in the induction of effective antitumor immunity, and the develop-
ment of therapeutic strategies based on monocyte reprogramming might be exploited for cancer
immunotherapy.
3.3. Myeloid-Derived Suppressor Cells
MDSCs are a heterogeneous myeloid cell population characterized by protumoral functions
such as the ability to abrogate adaptive antitumor immune responses and favor the metastatic























































































process (9). MDSCs have been abundantly observed in both tumor-bearing mice and cancer
patients to accumulate within primary tumor and metastatic lesions as well as in lymphoid
tissues, BM, and peripheral blood (80). Interestingly, circulating MDSC frequency is corre-
lated with the clinical outcome of patients treated with immunotherapy (81) as well as with
shorter overall survival and the development of metastatic disease in pancreatic cancer patients
(82). Currently, MDSC characterization is based on surface markers that define three main cell
subsets: monocytic-MDSCs (M-MDSCs) that are identified as CD11b+CD14+CD15−HLA-
DRlow/−CD124+ cells in cancer patients and CD11b+Ly6C+Ly6G− cells in tumor-bearing
mice; granulocytic-MDSCs (G-MDSCs) characterized as CD11b+CD14−CD15+HLA-DRlow/−
CD124+ cells and CD11b+Ly6C−Ly6G+ cells in humans and mice, respectively; and early
immature–MDSCs (eMDSCs) described as Lin−CD11b+CD34+CD33+CD117+HLA-DRlow/−
in human cells and CD11b+Gr1+CCR2+Sca1+CD31+ in mouse cells (83). Since MDSCs share
somemorphological and phenotypical features with their nonsuppressive counterparts, it is essen-
tial to confirm their identity with functional in vitro testing (83). Indeed,M-MDSCs isolated from
the blood of pancreatic cancer patients are clearly distinguishable from normal monocytes by their
cytological features (e.g., the presence of granules), molecular signatures, and immunosuppressive
properties but not by surface markers (82). M-MDSCs are generally more immunosuppressive
compared to G-MDSCs on a per cell basis both in tumor-bearing mice (84) and in cancer patients
(82), mainly due to contact-dependent but nonantigen-specific immune tolerance (26). Interest-
ingly, tumor-isolated M-MDSCs display a more potent suppressive activity than spleen-derived
MDSCs, suggesting that MDSC-mediated immunosuppression is dynamically enforced within
the TME more than in the periphery. The net result of these enhanced suppressive features is
the generation of a TME that prevents and inhibits T cell–mediated cancer elimination (9). In
addition, the tissue distribution of the M- and G-MDSC subsets is quite different: G-MDSCs are
preferentially located in the spleen, circulation, and BM, while M-MDSCs are enriched within
the majority of tumors (80); furthermore, M-MDSCs and G-MDSCs activate different pathways
for regulating cell-intrinsic death programs (26). In fact, c-FLIP and MCL-1 are essential for
the survival of M-MDSCs and G-MDSCs, respectively (26). Preventing the expression of c-FLIP
altered the immunosuppressive TME by reducing the number and activity of M-MDSCs (27).M-
MDSCs exhibit a higher cell plasticity compared toG-MDSCs; in the TME they act as precursors
of TAMs as well as transdifferentiate into G-MDSCs to maintain their level in the blood (85, 86).
Thus, it appears that the TME not only affects MDSC function but also modifies M-MDSC fate
by promoting their differentiation into more long-lived cells, such as TAMs. A critical role for
miR-142-3p in this process was recently suggested, since its downregulation was required for the
generation of immunosuppressive TAMs (87).Mechanistically,miR-142-3p downregulates gp130
by binding to the mRNA 3′ untranslated region and represses C/EBPβ LAP∗ by noncanonically
binding to its 5′ mRNA, impairing macrophage differentiation both in vivo and in vitro. Indeed,
tumor-bearing mice constitutively expressing miR-142-3p in the BM show an increase in sur-
vival following immunotherapy with antigen-specific T lymphocytes (87). M-MDSC plasticity
and function are strictly controlled by several signaling pathways (reviewed in 9, 80); specifically,
c/EBPβ, nuclear factor κB (NF-κB), and signal transducer and activator of transcription (STAT)3
have been reported to be involved in MDSC generation, differentiation, and function. The key
role of c/EBPβ in controlling MDSC generation was demonstrated using myeloid-restricted,
c/EBPβ-deficient mice engrafted with different tumor models, in which MDSC accumulation
was completely abrogated (35).NF-κB also regulates MDSC differentiation and function. Indeed,
MDSC immunosuppressive activity was recently linked to NF-κB p50 protein translocation into
the nucleus: By limiting the generation of p50:p50 homodimers through the abrogation of NF-κB
p50 nuclear translocation, MDSCs lose their immunosuppressive properties (88). In agreement























































































with these data, we demonstrated that c-FLIP promotes the nuclear translocation of NF-κB p50
protein, inducing immunosuppressive properties in monocytes independently of the antiapoptotic
properties of the protein (27). STAT3 protects MDSC survival by upregulating c-Myc, survivin,
and Cyclin D1 as well as by blocking cell differentiation through IRF8 (89). STAT3 also controls
several immunosuppressive circuits; in particular, STAT3 induces ARG1 by binding its specific
promoter (90) and also activates the production of proinflammatory soluble mediators (cytokines
and growth factors), such as S100A8/A9, which prevents MDSC conversion to DCs (91).
4. HOW THE TUMOR MICROENVIRONMENT SHAPES MONOCYTE
DIFFERENTIATION
Myeloid cell complexity depends on intrinsic local factors of the TME such as low levels of nutri-
ents, pH, and oxygen as well as cancer-released soluble factors and vesicles that are able to activate
stress-dependent molecular pathways in monocytes, shaping their phenotype and pro- or antitu-
mor function (Figure 2). Three main monocyte-shaping cues dominate the TME: environmental
stress, metabolic stress, and cell cross talk–dependent signals.
4.1. Environmental Stress Signals
In general, chronic stress and alterations to cellular homeostasis can steer tumor progression by
fueling inflammation, which is among the hallmarks of cancer (92). Stress signal pathways are
highly intertwined with each other and can shift the balance of protumor and antitumor elements
inside the TME.
One of the most prominent features of the TME is hypoxia, i.e., a nonphysiological level
of oxygen tension (0.1–3% O2), the combined result of anarchic vasculogenesis and intense
metabolic activity inside the tumor. Tumor-infiltrating monocytes and monocyte-derived cells
adapt themselves to the local conditions, stabilizing hypoxia-inducible factor 1α (HIF-1α) by acti-
vating oxygen-sensing rheostats including mTOR (mammalian target of rapamycin) and the un-
folded protein response (UPR) (93).HIF-1α transactivates a broad spectrum of genes that control
T cell activation, cell metabolism, cell recruitment, and cell differentiation (94). Indeed, tumor-
infiltrating MDSCs lacking HIF-1α are defective in generating TAMs but instead undergo con-
version to TADCs (95).HIF-1α increases ARG1 and iNOS expression in tumorMDSCs cultured
in vitro under hypoxic conditions; this can be halted by genetic deletion of HIF-1α, and abroga-
tion of the HIF-1α-mediated polarization of myeloid cells increased the efficacy of gp100-specific
T cell adoptive transfer combined with vaccination in controlling the outgrowth of melanoma
cells (95). Interestingly, hypoxic conditions fuel PD-L1 expression in both MDSCs and TAMs
within the TME. This process is mediated by direct binding of HIF-1α to the PD-L1 promoter
(96). Moreover, hypoxia orchestrates the angiogenic activities of MHC-IIlow M2-like TAMs, en-
abling the different spatial distribution of TAMs inside the TME,with increased infiltration of ei-
ther M2-polarized or M1-like TAMs in hypoxic versus normoxic tumor regions, respectively (66).
Contributing to the hypoxia-dependent alteration of the TME cell composition, the secretion of
soluble factors such as vascular endothelial cell growth factor (VEGF) and C-C motif chemokine
ligand (CCL)26 favors the recruitment of MDSCs and the migration of other VEGF receptor
(VEGFR)–positive cells such as Treg lymphocytes, exacerbating the TME immune impairment
(97). In response to hypoxia, TAMs andMDSCs release proteases [e.g., cathepsin and matrix met-
alloproteinase 9 (MMP9)], which sustain angiogenesis by freeing heparin-bound growth factors,
such as VEGF-A, and inducing extracellular matrix (ECM) remodeling (51). Although hypoxia


















































































































































































(a) Tumor-derived factors and tumor-supported conditions driving the differentiation of myeloid cells toward protumor phenotypes
and functions. (b) Tumor-derived factors and tumor-supported conditions driving the differentiation of myeloid cells toward antitumor
phenotypes and functions. Abbreviations: AP1, activator protein 1; ARG1, arginase 1; CD, cluster of differentiation; CHOP, CCAAT-
enhancer-binding protein homologous protein; c-FLIP, cellular FLICE (FADD-like IL-1β-converting enzyme)-inhibitory protein;
ECM, extracellular matrix; GCN2, general control nonderepressible 2; GLUT1, glucose transporter 1; GS, glutamine synthetase;
HIF-1α, hypoxia-inducible factor 1α; HSP90, heat shock protein 90; IDO, indoleamine 2,3-dioxygenase; IFN, interferon; IL,
interleukin; IRF, IFN regulatory factor; MHC-II, major histocompatibility complex II; MMP, matrix metallopeptidase; mTOR,
mammalian target of rapamycin; MyD88, myeloid differentiation primary response 88; NF-κB/p65-p50, nuclear factor κB protein 65
and 50; NADPH, nicotinamide adenine dinucleotide phosphate (reduced form); NO, nitric oxide; NOS2, nitric oxide synthase 2;
OGR1, proton-sensing ovarian cancer G protein–coupled receptor; OXPHOS, oxidative phosphorylation; PD-L1, programmed
death-ligand 1; PGE2, prostaglandin E2; PKM2, pyruvate kinase isozyme M2; PPARγ, peroxisome proliferator activated receptor γ;
RNS, reactive nitrogen species; ROS, reactive oxygen species; S100, S100 calcium binding protein; STAT, signal transducer and
activator of transcription; STING, stimulator of IFN genes; TGFβ, transforming growth factor β; TLR, Toll-like receptor; TME,
tumor microenvironment; TNF-α, tumor necrosis factor-α; VEGF, vascular endothelial cell growth factor; XBP1, X-box binding
protein 1. Figure adapted from an image created using Servier Medical Art (CC BY 3.0 Unported).























































































has been shown to promote the migration of CD8+ T cells into the TME, it also favors the in-
duction of T lymphocyte exhaustion through the expression of inhibitory receptors, such as PD-1
and CD223 [best known as lymphocyte activating gene 3 (LAG3)] (98). Since hypoxic condi-
tions in the TME not only drive the migration and conversion of monocytes but also reprogram
monocyte-derived cells into protumor elements, targeting hypoxic stress is considered a potential
strategy to shield or awaken antitumor immune responses.
Besides secreting immune-suppressive cytokines and chemokines, tumor cells produce large
amounts of lactic acid, which causes an acidification of the TME with profound consequences for
several immune cells and local inflammation. In fact, T cell proliferation and functions are inhib-
ited at acidic pH, as demonstrated by an increase in the apoptosis rate and a reduction in IL-2,
IFNγ, and perforin/granzyme (99). Local low pH enhances the expression of P-selectin glyco-
protein ligand 1 (PSGL-1) on tumor vascular endothelia, which facilitates monocyte migration
via P- or L-selectin binding, whereas acidic pH does not alter the expression of E-selectin, which
preferentially mediates T cell extravasation (100). Most importantly, low environmental pH in-
fluences monocyte-derived cell function inside the TME. For instance, monocyte-derived cells
express proton-sensing ovarian cancer G protein–coupled receptor (OGR1), a pH-sensing recep-
tor that reacts to extracellular protons and activates phospholipase C, triggering the secretion of
inflammatory cytokines such as TNF-α, IL-1β, and IL-6 (101). In an autocrine loop,macrophage-
derived TNF-α, synthesized in response to low pH, activates the NF-κB pathway, which upregu-
lates iNOS at both the mRNA and protein levels (64).Monocyte-derived cells can thus participate
in the early phases of tumor progression by sustaining precancerous inflammation, while in later
stages the low pH in the TME might be an important modulator of monocyte-derived cell func-
tions that enable tumor escape.
Environmental stress can rapidly disrupt correct protein folding and activate cell death
in resident TME cells, generating an increased local level of cellular debris that needs to be
eliminated by innate immune cells. These cellular components are able to alter the function of
phagocytes since they can deliver damage-associated molecular patterns (DAMPs) (102). DAMP-
mediated signals can promote TADC activation but also M2-like TAM polarization, as in the
case of high-mobility group protein B1 (HMGB1) signaling. This molecule has pleiotropic and
context-specific effects on TME-infiltrating immune cells; it fuels DC maturation and antitumor
immune responses via TLR4 in response to chemotherapy-induced immunogenic cell death
(102).However, it can also sustain IL-10 production after binding receptor for advanced glycation
end products (RAGE) in TAMs (103). Moreover, tumor cells undergoing genotoxic stress can
activate TME-infiltrating cells that express stimulator of IFN genes (STING), also known
as transmembrane protein 173 (TMEM173). The STING pathway is essential for detecting
cytoplasmic DNA. In fact, interactions between STING and cyclic GMP-AMP synthase (cGAS)
promote the activation of the TBK1-STAT6-IRF3 signaling cascade, which leads to type I IFN
release. Phagocytosis of tumor cells and DNA by TADCs after gaining access to the cytosol likely
triggers STING pathways that promote IFN-dependent priming of tumor-specific CD8+ T cells
(104). Also, some components of the ECM, such as versican, tenascin, and hyaluronic acid (HA),
are recognized as DAMPs by TLRs and promote changes in the recruitment, function, survival,
and activation states of monocyte-derived cells within the TME (105). HA-rich stroma recruits
TAMs, likely through the creation of an ECM scaffold that enhances chemokine retention. TAM
recruitment and the resulting sustained tumor angiogenesis can be abrogated by disrupting the
HA synthase 2 gene in stromal fibroblasts (106). Versican binding to TLR2 triggers a tolerogenic
phenotype in DCs through a doubly synergistic process: Induction of IL-6 and IL-10 synthesis
and expression of their cognate receptors sustain the activation of STAT3 signaling in an au-
tocrine manner while TLR2 blockade improves the antitumor functions of DCs and the efficacy























































































of immunotherapy (107). Tenascin also plays a role in the TME by inducing the phagocytosis
of CD47-deficient glioblastoma cancer cells and the release of proinflammatory cytokines (e.g.,
TNF-α) after triggering TLR4 in macrophages (108). Notably, apoptotic cell debris can be taken
up by macrophages using the Mer tyrosine protein kinase (MERTK) receptor, which activates an
immunosuppressive signaling program based on IL-10, ARG1, and transforming growth factor
β (TGFβ) (109). In agreement with these data, loss of MERTK increases iNOS expression in
macrophages and T cell infiltration into the TME (110).
Environmental pathophysiological conditions can activate endoplasmic reticulum (ER) stress
in tumor-infiltrating myeloid cells, since under these circumstances there might be an impair-
ment of the protein folding machinery or unrestrained protein synthesis and loading in the ER
lumen. In response to these alterations, an adaptive homeostatic response based on the UPR is
activated to restore ER proteases or induce apoptosis. The UPR fuels proinflammatory cascades
via NF-κB and JNK-AP1 activation, resulting in the production of protumor cytokines such as
IL-6, IL-23, and TNF-α (102). Moreover, APCs experiencing ER stress alter their antigen pro-
cessing machinery, resulting in defective presentation of immune-dominant peptides from tumor
antigens and, hence, decreased activation of antigen-specific T cells (102). Indeed, the conditional
deletion in DCs of X-box binding protein 1 (XBP1) compromises tumor progression by enhanc-
ing T cell activation in the TME; XBP1 is the main target of inositol-requiring enzyme-1α, a
major sensor of the UPR signaling cascade (111). Notably, TME-infiltrating MDSCs express
high levels of the ER stress–induced proapoptotic TF CHOP (CCAAT-enhancer-binding pro-
tein homologous protein), which is essential for their survival and immunosuppressive functions.
Another mechanism of immunosuppression that has gained attention as a potential therapeutic
target is the purinergic signaling axis, whereby the production of the purine nucleoside adeno-
sine (ADO) in the TME can effectively suppress T- and natural killer (NK)–cell function (112).
While the concentration of ADO in normal tissue is in the nanomolar range, it can swell to mi-
cromolar concentrations in solid tumors and is particularly enriched in the hypoxic tumor core
(113). The production of ADO is mediated by the cell-surface ectoenzymes CD73, CD39, and
CD38, and, once generated, ADO signals through the adenosine receptors (A1R, A2AR, A2BR,
A3R), members of the G protein–coupled receptor family. MDSCs and TAMs in the TME can
contribute to immunosuppression both by upregulating the ectoenzymes CD73 and CD39 and
by overexpressing A2BR/A2AR and A2BR/A2AR/A3R, respectively (114). Thus, macrophages
stimulated with ADO secrete increased amounts of IL-10 and less IL-12, TNF-α, and chemo-
tactic factors, dampening T cells’ killing activity. Using an elegant approach in which A2AR was
specifically eliminated in myeloid cells (by Lys-Cre-dependent deletion), it was shown that A2AR
limited antitumor immune responses, in part through the modulation of myeloid cells and the
subsequent enhancement of antitumor T cell responses (115). Similarly, A2BR blockade has been
shown to enhance antitumor immune responses, partly through a reduction in MDSC differ-
entiation (116) and enhancement of the capacity of DCs to evoke antitumor T cell responses
(117). A seminal study from the Sitkovsky group (112) demonstrated that the genetic deletion of
A2AR can enhance the responses mediated by activated anti-melanoma T cells in the TME. In
addition, the A2AR antagonist ZM241,385 was found to enhance the antitumor effect of CD8+
T cells in studies of lung metastasis that originated from a sarcoma model. More recently, CD73
and CD38 expression on tumor cells was shown to confer resistance to anti-PD-1 treatment,
since activation of T cells (i.e., the production of IFNγ) and PD-1 blockade upregulate the ex-
pression of A2AR, making these cells more susceptible to ADO-mediated suppression (118).
Hence, the inhibition of CD73, A2AR, or CD38 in combination with anti-PD-1 was shown to
elicit antitumor CD8+ T cell responses mediated by enhanced IFNγ and granzyme B release
(118).























































































4.2. Metabolic Stress Signals
It is well established that cancer cells undergo a metabolic shift toward relying on aerobic glycol-
ysis as the primary energy source to maintain their rapid proliferation. This process is called the
Warburg effect, and it is also utilized by tumor-infiltrating macrophages (119). Since metabolic
stress is not as well studied in other myeloid cells within the TME, we mainly focus here on
TAMs. It may seem counterintuitive that activated cells like macrophages use glycolysis as their
main energy source, as oxidative phosphorylation (OXPHOS) produces 36 molecules of ATP
compared to glycolysis, which generates a mere 2 ATP per molecule of glucose. However, gly-
colysis can be switched on faster than OXPHOS since it does not require mitochondrial bio-
genesis, and it provides essential biosynthetic intermediates to be used in other cellular pro-
cesses. Glycolysis is an essential metabolic activity for M1-polarized macrophages since it can
affect several functions that are generally controlled by the activation of the TF HIF-1α, such as
phagocytosis, ROS production, and secretion of proinflammatory cytokines (120). Indeed, HIF-
1α regulates the expression of genes encoding for glycolytic enzymes and transporters such as
GLUT1 (121), which facilitates glucose uptake in M1-polarized macrophages. In contrast, M2
macrophages rely on OXPHOS over glycolysis as their main source of ATP (122). Evidence for
this distinction was obtained by using extracellular flux analysis to study the metabolic features
of classical and alternative macrophages (122). Moreover, IL-10 suppresses glycolysis in in vitro–
differentiated macrophages, highlighting how a Warburg-like effect is predominantly associated
with M1-polarized macrophages. Conversely, M2 macrophages display an increased rate of ox-
idative metabolism as well as amplified mitochondrial metabolism (123). In alternatively activated
macrophages, glucose metabolism is normally regulated by mTOR through an AKT-dependent
pathway; however, this process is modulated by several environmental signals, such as IL-4 and
M-CSF, that enforce the use of glycolysis via the mTOR/IRF4 pathway. This increased glycolysis
during M2 activation also reduces glucose availability for M1-polarized macrophages (124). This
aspect of M2 macrophage metabolism suggests that they have a more flexible metabolism since
they can supply OXPHOS even in the absence of glycolysis by using glutamine (122). Several
glycolytic enzymes influence the functional properties of monocyte-derived cells. Among them,
pyruvate kinase M2 (PKM2) acts in M1-polarized macrophages as a nuclear coactivator of HIF-
1α, promoting the expression of proinflammatory cytokines such as IL-1β via direct binding to the
hypoxia response element site of their promoters (125). Notably, PKM2 has also been shown to
regulate PD-L1 expression in bothmacrophages and other immune cells; indeed, the PKM2/HIF-
1α complex specifically binds the promoter of the PD-L1 gene (126).
Other metabolic pathways, such as lipid and amino acid metabolism, are adapted by tumor-
infiltrating, monocyte-derived cells in response to TME nutrients. Fatty acid synthesis and fatty
acid beta oxidation are strictly controlled and take place in different cellular compartments, i.e.,
the cytosol and mitochondria, respectively. Fatty acid synthesis is closely linked to the proinflam-
matory functions of myeloid immune cells and monocyte conversion into macrophages under M-
CSF-driven differentiation (127). In agreement with these observations, a newly identified protein
named FAMIN is actively involved in de novo lipogenesis but also regulates the inflammasome and
the release of inflammation-associated cytokines in macrophages (128).Notably, alterations to the
triglyceride biosynthetic pathway in DCs significantly impair their ability to activate antitumor
responses by priming T cells (111). Lipolysis in the TME produces free fatty acids that are taken
up by CD36-expressing monocyte-derived cells that mostly resembleM2-polarized macrophages.
M2 macrophages rely on fatty-acid uptake and oxidation to stimulate the activation of STAT6-
and peroxisome proliferator-activated receptor γ (PPARγ)-dependent programs (129).























































































The extracellular amino acid reservoir is directly related to the activation state of immune cells
inside the TME.The first evidence that amino acid metabolism can regulate macrophage function
comes from data on the ability ofmacrophages to block tumor growth through the consumption of
arginine (130). The consumption of amino acids strongly affects the immune cell composition of
the TME, and it represents a key process required for monocyte-derived cells to abolish adaptive
immune responses (described in Section 4.3). Glutamine metabolism has a profound impact on
both tumor growth and the cellular composition of the TME.M2-like macrophages express high
levels of glutamine synthase (GS), the glutamine-synthesizing enzyme that controls the activation
of several metabolic mediators, including the key sensor mTOR (131). Pharmacological inhibition
of GS skewsM2-polarized macrophages toward theM1-like phenotype, which is characterized by
reduced intracellular glutamine and increased succinate, enhanced glucose flux through glycolysis,
and HIF-1α activation. As a result of these metabolic changes and HIF-1α accumulation, GS-
inhibited macrophages have an increased capacity to induce T cell recruitment, a reduced ability
to suppress T cells, and an impaired ability to foster endothelial-cell branching and cancer-cell
motility. Thus, blocking glutamine metabolism would not only reduce tumor growth but also
restore an effective antitumor response (132), supporting the use of glutamine-pathway inhibitors
to treat cancer.
4.3. Cell Cross Talk–Dependent Signals
Interactions among neighboring cells in the TME are indispensable for tumor growth and de-
velopment. Besides direct cell-cell contact, intracellular communication involves complex systems
using secreted factors. Several factors released by cancer cells can regulate the generation, differen-
tiation, and function of tumor-infiltratingmonocyte-derived cells. Among them, prostaglandin E2
(PGE2), which is secreted by various cancer types, plays multiple roles in the recruitment and con-
version ofmonocytes. Indeed, it inhibits cancer-cell secretion ofCCL5 and other proinflammatory
components and limits the expression of CCR5 in TAMs, but at the same time, it prompts the re-
lease of MDSC chemoattractants such as C-X-C motif chemokine ligand (CXCL)12 (133). The
genetic ablation of cyclooxygenase 1 (COX1), an enzyme critical for the production of PGE2, sig-
nificantly increases trafficking of DCs and their expression of IL-12 and costimulatory molecules
in preclinical models of melanoma tumors. In accordance, COX1 inhibition synergizes with anti-
PD-1 blockade in controlling tumor growth, suggesting that COX inhibitors could be useful ad-
juvants for immune-based therapies in cancer patients (134). Other tumor-derived soluble factors
such as cytokines also regulate myeloid cells’ identity and function. Well-characterized examples
are IL-4, IL-10, and TGFβ (5). In the last few years, attempts to understand the role of tumor-
derived exosomes (TEXs) in modulating the TME have been of great interest. Exosomes are
nanometer-sized membranous vesicles packed with proteins, lipids, DNA, mRNA, and microR-
NAs (135). Interestingly, exosomes are generally present at higher concentrations in the blood of
cancer patients compared to healthy controls, and their cargo can vary according to the patient’s
disease, suggesting that cancer cells might use exosome-mediated communication to modify not
only local immune responses but also distal immune sites (136). In line with this hypothesis, re-
cent data clearly highlight the ability of TEXs to edit and program premetastatic and metastatic
niches (137). Normally, TEXs activate NF-κB-dependent pathways in macrophages, leading to
the release of IL-6 and TNF-α and thus promoting the proliferation of cancer cells (135). More-
over, TEXs favor the expression of PD-L1 in MDSCs (138). However, TEXs may contribute to
efficient DC-mediated priming of antitumor adaptive responses (135). Macrophage-derived ex-
osomes can also affect tumor-cell biology. In fact, macrophage-derived exosomes can promote























































































tumor invasion by transferring Wnt5a to cancer cells, leading to the activation of the β-catenin-
independent Wnt signaling pathway; M2 TAM-derived exosomes containing miR-21 can also
mediate resistance to cisplatin chemotherapy through the activation of the phosphoinositide 3-
kinase (PI3K)/AKT pathway, which promotes prosurvival functions in gastric cancer cells (139).
These data suggest the existence of a bidirectional exosome-mediated engagement between cancer
cells and tumor-infiltrating myeloid cells in the TME.The use of standardized protocols for TEX
isolation and characterization is essential for studying exosome biogenesis and the mechanisms of
exosomal cargo delivery. Taking current limitations into account, TEXs may provide a new source
of biological markers for predicting patient prognosis or response to therapy as well as important
targets for developing therapeutic strategies based on exosome-mediated communication between
TME elements.
5. HOW MONOCYTE-DERIVED CELLS SHAPE THE TUMOR
MICROENVIRONMENT
Tumor-infiltrating monocyte-derived cells support tumor growth through both immunological
and nonimmunological mechanisms.
5.1. Promotion of Immune Dysfunction
MDSCs and TAMs synergize to establish local and peripheral tolerance, which hides tumors
from the effector arm of the immune system. To this end, myeloid cells use an array of cytokines,
metabolites, and surface receptors that directly affect the function of innate and adaptive immu-
nity by both directly modulating the fitness of NK and effector T cells and indirectly skewing the
polarization status of other immune subsets toward a suppressive phenotype, i.e., pDCs,Tregs, and
regulatory B lymphocytes (86). TAMs andMDSCs deplete the TME of arginine, tryptophan, and
cysteine, essential amino acids for T cells, through the cooperative catabolism of iNOS, ARG1,
and indoleamine 2,3-dioxygenase (IDO) enzymes.
Arginine deprivation has multiple negative effects on T cell function. It rewires T cell
metabolism by switching it fromOXPHOS to glycolysis, reducing T cell fitness, central memory–
like functions, survival, and antitumor efficacy (140). The transcription regulators BAZ1B, PSIP1,
and TSN are responsible for arginine sensing in the TME, modifying metabolism and regulat-
ing prosurvival actions in T lymphocytes. Accordingly, arginine deprivation affects the expres-
sion of the TFs E2F1, cdk2, and cyclin D3, which in turn prevent cell cycle progression at the
G0/G1 phase, resulting in proliferative arrest of T cells (9). Moreover, arginine starvation re-
sults in reduced TCR signaling due to the downregulation of the CD3ζ chain, which limits IFNγ
release and T cell function (141). ARG1 and iNOS are the two main enzymes involved in argi-
nine catabolism. ARG1, which is mainly produced by M2-polarized macrophages and MDSCs,
metabolizes arginine to urea and ornithine and is considered a marker of immunosuppression in
myeloid cells (141). Its expression is regulated by cytokines (i.e., IL-4, IL-6, IL-10, and IL-13),
prostaglandins, tumor metabolic products such as lactic acid, and hypoxia (141). Pharmacological
blockade of ARG1 or genetic deletion inmyeloid cells results in improved immunotherapy efficacy
(79). Interestingly, T cells are also endowed with cell-autonomous arginine-dependent regulatory
pathways that depend on the activity of mitochondrial ARG2, which intrinsically regulates T cell
function, proliferation, differentiation, and antitumor activity in vivo (142).
iNOS competes with ARG1 for arginine as a substrate to generate NO and citrulline.
However, iNOS’s immunosuppressive and protumor contribution is more context dependent.
Indeed, iNOS is considered a classic hallmark of antitumor M1-polarized macrophages, and























































































its upregulation has a beneficial effect on host immunity and tumor restriction in both TAMs
(64) and tumor-infiltrating Tip-DCs (79). However, iNOS is also expressed by MDSCs and
is responsible (sometimes together with ARG1) for MDSC-mediated suppression of T cell
proliferation and activity (35, 84). NO negatively affects IL-2R signaling and promotes T cell
apoptosis through p53 accumulation and Fas (CD95/APO-1) signaling (80). The genetic deletion
of iNOS in MDSCs completely restores T cell proliferation (79). Similar to arginine, tryptophan
shortage has multiple negative consequences for T cell proliferation and function.
Tryptophan deprivation activates the amino acid sensor general control nonderepressible
2 (GCN2) through its binding to uncharged tRNAs, which results in the phosphorylation of
polypeptide chain initiation factor 2 subunit α (eIF2α). This posttranslational modification de-
creases the turnover of eIF2α and dramatically affects protein synthesis by interrupting mRNA
translation and downstream cellular functions, such as proliferation and activation (143). Trypto-
phan starvation also results in downregulation of the CD3ζ chain and impairment of TCR down-
stream signaling in T cells (144). Notably, GCN2 was recently reported to drive and sustain the
immunosuppressive functions of MDSCs in the TME (145). IDO is the main enzyme expressed
by tolerogenic DCs and MDSCs responsible for tryptophan catabolism into kynurenines. The
latter molecules have immune regulatory functions as well: By interacting with the aryl hydrocar-
bon receptor, they trigger CD4-expressing lymphocytes and DCs to differentiate toward Tregs
and pDCs, respectively (144).
Cysteine is another limiting amino acid for protein biosynthesis and T cell function. This
molecule can be obtained by converting methionine with cystathionine γ-lyase or imported in its
oxidized form (cystine) from extracellular space via the SLC7A11 cystine/glutamate antiporter.
T cells, which do not express any of these proteins, mostly rely on amino acids provided by
macrophages and DCs that reduce cystine to cysteine and release it through the alanine-serine-
cysteine (ASC) transporter. In contrast,MDSCs do not express ASC and store cystine and cysteine
for their own use as a source of glutathione, an antioxidative molecule that can detoxify cells from
the dangerous consequences of the free radicals they produce (146).
Macrophages and MDSCs are the main source of ROS within the TME. ROS include hydro-
gen peroxide, singlet oxygen, superoxide anions, and hydroxyl radicals that are generated during
electron transfer from nicotinamide adenine dinucleotide phosphate (NADPH) to oxygen in a
reaction catalyzed by the NADPH oxidase (NOX) protein family. ROS generation has a direct
negative impact on IFNγ secretion and the proliferation of antigenic-specific T cells by reducing
the CD3ζ chain and an indirect role in the evolution of the immune-suppressive tumor milieu by
inhibitingM-MDSC differentiation towardmacrophages andDCs, supporting the recruitment of
other MDSCs, and increasing VEGFR expression and STAT3 signaling in an autocrine manner
(147).
NOX2 genetic deficiency disrupts MDSC-dependent suppression of T cell function and
enhances MDSC differentiation toward macrophages and DCs (147). More importantly, NO
generated by iNOS quickly reacts with ROS to produce more dangerous and reactive nitrogen
species (RNS), which have additional negative effects on T cell recruitment and function. Indeed,
both ROS and RNS avidly react with macromolecules (i.e., lipids, nucleic acids), modify the
tridimensional structure of proteins (by preferentially nitrating tyrosine residues), and conse-
quently impair the signaling pathway activity and biological processes of innate and adaptive
immunity. For example, RNS can affect both the trafficking and function of T lymphocytes
by modifying chemokines (e.g., CCL2 and CCL5), altering antigen presentation and peptide
loading ontoMHC-I molecules, or affecting the TCR structure to prevent signaling and promote
dissociation of the CD3ζ chain (148). Notably, TME preconditioning with an NO donor named
[3-(aminocarbonyl)furoxan-4-yl]methyl salicylate (AT38), which is able to limit endogenous NO























































































production by iNOS and ARG1 expression in myeloid cells, efficiently restores T cell infiltration
within the tumor and improves the efficacy of T cell adoptive therapy (149). RNS can also
negatively affect the FcR-mediated functions of NK cells such as antibody-dependent cellular
cytotoxicity and cytokine secretion, thus impairing the efficacy of antibody-based immunotherapy
in pancreatic cancer (150).
ARG1 and iNOS targeting represents a valid strategy to neutralize MDSC-triggered immune
suppression; however, the current literature suggests that myeloid cells can also use receptor-
ligand interactions to induce T cell apoptosis. Indeed, PD-L1 expression by MDSCs and TAMs
was reported in solid tumors with different histology, and the efficacy of anti-PD-1 therapy (alone
or in combination with CTLA4) in melanoma and ovarian cancer patients was directly correlated
with the expression of its ligand on TAMs and monocytes rather than on tumor cells (151). B7H4
is another immune-checkpoint molecule expressed on monocytes and TAMs in ovarian and liver
cancers (152, 153) that plays a negative role in T cell function. Its expression is induced by the
cytokines IFNγ, IL-6, and IL-10, and, after interacting with an unknown receptor on T cells,
B7H4 impairs IL-2 production and induces cell exhaustion. Ectopic expression of B7H4 turns
normal macrophages into suppressive cells (152), whereas its pharmacological inhibition restrains
the growth of subcutaneous tumors and synergizes with anti-PD-1 to enhance antitumor immune
responses (153).
Macrophages also express a variety of lectins, which can have a potential role in tuning T cell
responses.Mannose receptor (CD206), for example, has been shown to inhibit CD45 phosphatase
activity in CD8+ T cells, resulting in impaired cytotoxic activity (154). Both CTLs and myeloid
cells use receptor-ligand interactions that can directly target tumor cells to induce apoptosis, such
as the interaction between Fas ligand and TNF-related apoptosis-inducing ligand (TRAIL); how-
ever, tumors can hijack these proapoptotic pathways to establish a microenvironment that assures
its outgrowth and invasion. TRAIL-resistant tumor cells respond to TRAIL-receptor triggering
by activating aTRAIL-dependent secretome in a FADD- and caspase-8-dependentmanner,which
drives monocyte polarization to MDSCs and M2-like macrophages (25). Moreover, myeloid cells
can trigger Fas-mediated apoptosis of T lymphocytes, contributing to the establishment of an
immune-suppressive microenvironment (155).
Tumor-infiltrating, monocyte-derived cells display membrane B7-1 and B7-2 proteins, which
can have either protumor or antitumor activity by triggering CTLA4 or CD28 receptors exposed
on T cell membranes, respectively (156). Tumor and stromal cells synergize to establish an im-
munosuppressive milieu by releasing an array of cytokines and chemokines that orchestrate the
infiltration and polarization of immune-suppressive leukocyte subsets. This is the case for TGFβ,
whose production by monocyte-derived macrophages and MDSCs is a major source of the cy-
tokine in the TME. TGFβ has multiple negative effects on tumor immunity: excluding T cell
infiltration in the tumor bed (157), sustaining Treg generation, and impairing effector T cell and
NK function (158). MDSCs and TAMs also shift the IL-10/IL-12 balance toward increased IL-
10; more specifically,MDSCs skew the polarization of TAMs andDCs toward protumor elements
via the release of IL-10. TAM-derived IL-10 has negative effects on T cell immunity, as indicated
by the experimental observation that IL-10 pharmacological blockade can interrupt this switch
by inducing IL-12-producing CD103+ DCs that are able to support T cell antitumor functions
in breast cancer models (159).
5.2. Promotion of Tumor Growth by Other Mechanisms
Recent findings confirm the hypothesis that TAMs and MDSCs can directly support tu-
mor growth through mechanisms that extend beyond the regulation of the antitumor immune























































































response. Indeed,myeloid cells play a pivotal role in sustaining the metabolic needs of tumor cells,
assisting tumor evolution during all phases of progression, from the initial oncogenic cascade to
its spread to distal anatomical sites (160). The increased demand for nutrients and oxygen sensed
by HIF-1α triggers the release of inflammatory cytokines in glioblastoma cells, including stromal
cell-derived factor-α (SDF1α), which supports the infiltration of inflammatory monocytes. The
recruited cells in turn increase VEGF availability via MMP9-mediated matrix remodeling (93).
A self-perpetuating positive loop also sustains tumor angiogenesis: TNF-α and VEGF released
in the TME supports the infiltration of both intermediate and classical monocytes, which in turn
increase VEGF availability via MMP9 activity (161). MDSCs can also contribute to angiogenesis
by activating a Bv8-dependent pathway that bypasses VEGF restriction (9, 80). Refractoriness
to antibody-mediated antiangiogenic therapy in colorectal cancer is linked to SDF1α secretion
in the TME, supporting the hypotheses that many compensatory mechanisms sustain tumor
angiogenesis and that myeloid cells play a pivotal role in these processes (162). Thus, a therapeutic
approach with multiple targets is necessary to restrict the supply of nutrients to cancer (163).
MDSCs and TAMs are able to shape the tumor ECM to support tumor proliferation and pro-
mote cell invasion by releasing an array of digestive enzymes, including cathepsins and MMPs
(164). However, TAMs also support tumor metastases by directly guiding tumor cells across the
ECM toward the basal membrane and endothelium, opening a gate for tumor-cell entry into the
blood. This is mediated by the establishment of a paracrine signaling loop between CSF-1 and
epidermal growth factor (EGF) between the two cells, which can be interrupted by inhibiting
either CSF-1R or EGFR downstream signaling (165). Accordingly, EGF and CSF-1 expression
in TAMs and tumor cells, respectively, are independent markers of poor prognosis in breast can-
cer (56). Tumor-infiltrating, monocyte-derived cells also support the metastatic process by induc-
ing the epithelial-to-mesenchymal transition (EMT). By activating a β-catenin-mediated pathway,
macrophage-derived TGFβ inhibits expression of the epithelial marker E-cadherin and increases
the expression of mesenchymal markers, triggering an invasive phenotype in breast cancer cells
(166). These findings are clinically relevant since macrophage infiltration and TGFβ levels are
positively correlated with mesenchymal markers and tumor grade in non–small cell lung cancer
patients (166).
ECM composition plays an important role in defining the fate of tumor cells: Secreted pro-
tein acidic and rich in cysteine (SPARC)-rich ECM is associated with poor clinical outcomes and
preferential EMT in breast cancer. SPARC orchestrates the infiltration and immune-suppressive
function of MDSCs (88), and targeting of MDSCs with aminobisphosphonates [zoledronic acid
(ZA)] is able to reverse the EMT (167). Indeed, ZA treatment affects both MDSC-dependent
immune-suppressive and protumor functions by directly impairing STAT3, ARG1, and TGFβ
expression, resulting in increased T cell proliferation and higher E-cadherin expression on tumor
cells.
TAMs and MDSCs revert senescence in tumor cells and support cancer stem cells (CSCs) via
many mechanisms. TAM-derived IL-6 activates STAT3-induced expansion of CD44+ hepatocel-
lular carcinoma (HCC)-derived cells, the formation of spheroids in vitro, and tumor establishment
in vivo. Importantly, levels of IL-6 are clinically correlated with cancer progression and markers
of CSCs in HCC (168).However, TAMs also sustain CSCs through juxtacrine signaling mediated
by activating CD90 and Ephrin-4 receptors on breast CSCs. This interaction activates signaling
via the Src and NF-κB pathways and ends in the secretion of an array of cytokines (i.e., IL-6, IL-
8, and GM-CSF) that sustain the EMT state of CSCs (169). MDSCs revert cancer senescence in
PTEN-null prostate cancer in a paracrine manner by releasing IL1-RA, and strategies that target
MDSC expansion or genetically delete IL1-RA critically affect this process (170).























































































Monocytes can either contribute to or limit metastatic spreading depending on their origin and
polarization status. Inflammatory CCR2+ monocytes are recruited to primary breast tumors fol-
lowing CCL2 secretion by tumor and stromal cells; at the premetastatic site, they support tumor
extravasation in a VEGF-dependent manner (171). CCL2 and macrophage infiltration are corre-
lated with worse clinical outcomes and higher metastatic probability in breast cancer patients.The
pharmacological inhibition of CCL2-CCR2 signaling (by targeting either CCL2 or CCR2) de-
creases inflammatory monocyte recruitment to primary tumors, thus reducing metastatic spread-
ing and increasing mouse survival (171). Patrolling monocytes control tumor seeding in the lungs,
fostering cancer immune surveillance in many mouse tumor models, including breast cancer. In-
deed, their removal by Nr4a1 genetic deletion resulted in higher metastatic spreading (172). Even
if the underlying mechanism is not completely defined, it involves efficient patrolling by mono-
cytes to remove tumor material engulfed in the lung vasculature in a C-X3-C chemokine receptor
(CX3CR)1-dependent manner and promotes the recruitment and activation of NK cells (172).
6. CONCLUDING REMARKS
Accumulating evidence indicates that tumors influence monocyte fate inside the TME, favoring
the accumulation of protumoral cells with angiogenic, trophic, and immunosuppressive proper-
ties.However, this tumor imprinting is reversible since monocyte-derived cells maintain plasticity,
which allows them to be reprogrammed into antitumor elements. Rewiring tumor-infiltrating,
monocyte-derived cells has been shown to induce antitumor effects in preclinical models (173,
174). Indeed, strategies to directly manipulate the transcriptional programs in monocyte-derived
cells have been developed, including methods to modulate key signaling pathways associated with
immune suppression, i.e., the STAT3, NF-κB, and PI3Kγ pathways. Furthermore, combined ac-
tions might improve the final pharmacological activity: For example, PI3Kγ targeting inhibits not
only the growth of tumor vasculature but also local immunosuppression by reducing immunosup-
pressive TAMs or stimulating TADCs to produce cytokines that induce effective T cell responses
(175).The CD40:CD40 ligand axis may represent another interesting target for turning immuno-
suppressive cells into effective APCs. Indeed, agonistic CD40 antibody-based therapies abrogate
MDSC:Treg cross talk, convert MDSCs into functional T cell–priming cells, and prompt TAMs
to exert tumoricidal activity (176). Therefore, a new era of cancer immunotherapy based on tar-
geting tumor-infiltrating myeloid cells to enhance current therapeutic protocols is just around
the corner. More caution is warranted when neutralizing immune factors that are not unique to
tumors and their TMEs (e.g., iNOS) since they are essential for maintaining body homeostasis.
Blocking these factors will require the targeting of specific cell subsets that are induced by cancer
programming. Thus, to develop future therapies, it will be essential to expand our knowledge of
the mechanisms regulating monocyte differentiation inside the TME. In particular, we need to
decipher the complex repertoires of tumor-infiltrating myeloid cells by applying novel technolo-
gies (e.g., single-cell RNA-seq approaches) to precisely map the steps that monocytes take as they
differentiate into either tumor-promoting or tumor-suppressing cells.
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